Evidence map›Paper›PMID 27430294›Full record

Trial reportBMC nephrology2016

Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.

Lauren B Beach, Marcus Wild, Gowri Ramachandran, H Omer Ikizler, Kerri L Cavanaugh

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01992926 (Facilitating Anemia Treatment Risk Communication for Patients With Kidney Disease), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01992926 nacompletednot on this map

Facilitating Anemia Treatment Risk Communication for Patients With Kidney Disease: Decision Aid Trial

TypeinterventionalSponsorVanderbilt UniversityRan2013 to 2014Enrolled109ConditionsChronic Kidney Disease, End Stage Renal DiseaseArmsinteractive educational intervention
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Decision aids for people facing health treatment or screening decisions.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Systematic Development of Patient Decision Aids: An Update from the IPDAS Collaboration.Medical decision making : an international journal of the Society for Medical Decision Making · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Lauren B BeachDivision of Nephrology & Hypertension, Vanderbilt University Medical Center, 1161 21st Avenue South, S-3223 MCN, Nashville, TN, 37232, USA.
Marcus WildDivision of Nephrology & Hypertension, Vanderbilt University Medical Center, 1161 21st Avenue South, S-3223 MCN, Nashville, TN, 37232, USA.
Gowri RamachandranUniversity of Toledo College of Medicine, Toledo, OH, USA.
H Omer IkizlerUniversity of Vermont College of Medicine, Burlington, VT, USA.
Kerri L CavanaughDivision of Nephrology & Hypertension, Vanderbilt University Medical Center, 1161 21st Avenue South, S-3223 MCN, Nashville, TN, 37232, USA. kerri.cavanaugh@vanderbilt.edu.ORCID 0000-0002-4031-1714
Vanderbilt University · USUniversity of Toledo · USUniversity of Vermont · US

Funding

The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
VANDERBILT NEPHROLOGY TRAINING PROGRAMT32DK007569 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARRIS, RAYMOND C., IKIZLER, TALAT ALP · 1988 to 2024
$5.8M
Vanderbilt O'Brien Mouse Kidney Physiology and Disease CenterP30DK079341 · NIDDK · VANDERBILT UNIVERSITY · PI HARRIS, RAYMOND C. · 2008 to 2013
$4.4M
Vanderbilt Student Research Training ProgramT35DK007383 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI William Heerman · 1986 to 2026
$4.1M
Determining Key Organizational Health Communication Practices in Complex PatientsR01DK103935 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CAVANAUGH, KERRI · 2015 to 2019
$2.0M
Facilitating Anemia Treatment Risk Communication for Patients with Kidney DiseaseR03DK093852 · NIDDK · VANDERBILT UNIVERSITY · PI CAVANAUGH, KERRI · 2012 to 2013
$153k
NCATS NIH HHS UL1 TR000445NIDDK NIH HHS P30 DK079341NIDDK NIH HHS R01 DK103935NIDDK NIH HHS R03 DK093852NIDDK NIH HHS T32 DK007569NIDDK NIH HHS T35 DK007383
6 · The paper itself

Abstract

backgroundErythropoiesis-stimulating agents (ESAs) are commonly used for the treatment of anemia due to chronic kidney disease (CKD) and end stage renal disease (ESRD). Patients often lack an understanding of the potential risks and benefits of ESAs, despite government mandated education on this topic. Decision aids are tools commonly used to discuss important information in health care settings. To address this knowledge gap, we designed this study to evaluate the effectiveness of a novel ESA decision aid at promoting informed shared decision making (ISDM) between patients and providers related to ESA use for CKD- and ESRD-related anemia.

methodsUsing the principles of informed shared decision making theory, we designed and piloted an ESA decision aid intended to increase CKD and ESRD patient understanding of the potential risks and benefits of ESAs. Informed by the findings during development, the ESA decision aid was modified and finalized for testing. We will perform a randomized clinical trial to assess if administration of the ESA decision aid improves patient understanding of the risks and benefits of ESA use compared to control patients receiving standard care. Participants with either CKD or ESRD and who are receiving ESAs will be eligible for participation. The primary outcome is patients' score on the Patient Anemia Knowledge in Kidney Disease (PAKKD) survey assessed at enrollment and 3 months after. Secondary outcomes include decisional conflict related to ESAs, and patient satisfaction with provider communication. DISCUSSION: The Anemia Risk Communication for patients with Kidney Disease (ARC-KD) study will assess the effectiveness of a novel ESA decision aid to improve patient understanding of ESA use to manage CKD- and ESRD-related anemia. This decision aid is the first resource targeted to improve patient understanding of anemia management in the kidney health context. With the increasing options available for anemia management, this will serve as an important foundation to evolve in the future to optimize anemia-related shared decision making.

trial registrationClinicalTrials.gov, number NCT01992926 . Registered 11/14/2013.

Indexed as

AdolescentAdultAgedAged, 80 and overAnemiaClinical Decision-MakingErythropoietinFemaleFollow-Up StudiesHematinicsHemoglobinsHumansMaleMiddle AgedRenal Insufficiency, ChronicSingle-Blind MethodErythropoietinHematinicsHemoglobinsAnemiaChronic kidney diseaseDecision aidDialysisEnd stage renal diseaseErythropoietin stimulating agentIPDASPatient provider communicationShared decision making

Identifiers

PMID27430294
PMCPMC4949884
OpenAlexW2503650897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.